Austin, Texas — MindWalk Holdings Corp. has filed a European patent application covering high-dimensional biological data structures used in its artificial intelligence-driven drug discovery platform.
The company said application No. EP26187897.9 is intended to protect the biological representation architecture underlying its HYFT® Technology, ReefIQ™ biological context layer and LensAI™ reasoning workflows.
The architecture organizes biological information around HYFT pattern anchors, allowing AI systems to retrieve, compare and analyze connected biological data while preserving context and traceability.
“As AI models become more broadly available, we believe lasting advantage in life sciences will come from the biological context those models can use. The differentiator is not a generic AI interface, but the structured biological representation that lets models and agentic workflows retrieve connected evidence, preserve provenance, and reuse knowledge across programs. This filing is intended to protect aspects of the architecture at the core of HYFT® Technology, where MindWalk believes lasting value in biological AI can compound,” said Jennifer Bath, Ph.D., Chief Executive Officer and President, MindWalk Holdings Corp.
The new application builds on MindWalk’s foundational HYFT patent, EP3881326A1, which covers the identification of recurring biological patterns and their use as a searchable language for comparing sequences without alignment.
MindWalk said the new filing addresses an additional layer that connects those patterns with sequence, structural, physicochemical, functional, experimental, literature-derived and program-history information.
The company said the model-agnostic architecture is designed to complement protein large language models and other AI systems by allowing biological knowledge to be reused across discovery programs, customer projects and software workflows.
“Biology does not live in one file type. Sequence, structure, physicochemical behavior, function, evidence, and literature all need to stay connected for AI systems to be useful in discovery. Through this filing, we are seeking to protect the layer that keeps those biological connections organized, accessible, and usable as discovery work moves between AI models, software tools, and human scientific teams. That is the layer we believe can make AI workflows more grounded, more reusable, and more valuable over time,” said Dirk Van Hyfte, M.D., Ph.D., Chief Technology Officer, MindWalk.
MindWalk has begun applying the technology in preclinical dengue and influenza programs. In dengue research, the company said a HYFT-identified target informed immunogen design and generated antibodies that bound across antigens from all four dengue serotypes in two independent campaigns.
In influenza, the company has identified a HYFT-defined functional constraint across influenza A and B datasets, including human, avian, swine-associated, Victoria and Yamagata backgrounds.
The company said the programs remain preclinical and require additional studies to assess neutralization, safety, durability, clinical translation, regulatory pathways and commercial potential.
MindWalk said ReefIQ and LensAI are the commercial applications of the architecture. LensAI is currently used in recurring arrangements with life sciences customers to support target discovery, candidate evaluation, hypothesis generation and portfolio decision-making.
